Article Impact Level: HIGH Data Quality: STRONG Summary of Annals of Internal Medicine https://doi.org/10.7326/ANNALS-25-02221 Dr. Malahat Khalili et al.
Points
- Researchers conducted a systematic review of forty-three clinical trials to identify the most effective pharmacologic prophylactic treatments for adults suffering from fifteen or more migraine days each month.
- The analysis found that newer calcitonin gene-related peptide targeted therapies successfully reduced monthly migraine days by approximately two while maintaining high levels of patient tolerability and adherence.
- Clinical data suggested that botulinum toxin injections may offer some benefits for chronic headache sufferers but were often associated with a higher risk of bias and treatment discontinuation.
- Investigators determined that older medications such as topiramate and propranolol provided less reliable evidence for prophylaxis compared to newer biologic treatments due to significant limitations in trial data.
- These findings emphasize that while newer therapies show great promise clinicians should consider cost and individual patient preferences when selecting the most appropriate long-term migraine management strategy.
Summary
This systematic review evaluated the comparative effectiveness and tolerability of various pharmacologic prophylactic treatments for chronic migraine in adults. Given that chronic migraine is defined by headaches occurring on 15 or more days per month and significantly impairs quality of life, the research sought to synthesize data from 43 clinical trials to determine which interventions provide the most robust therapeutic benefit. The analysis scrutinized a spectrum of options, including newer monoclonal antibodies and small-molecule antagonists, alongside traditional oral preventives and injectable toxins.
The meta-analysis revealed that calcitonin gene-related peptide (CGRP)-targeted therapies, such as eptinezumab and atogepant, demonstrated the strongest evidence for efficacy, reducing monthly migraine days by approximately 2 days compared to placebo. These newer agents were generally well-tolerated and featured a lower side-effect profile than older systemic medications. In contrast, while botulinum toxin A (Botox) showed potential benefits, the supporting evidence was categorized with lower certainty and associated with higher rates of adverse events, contributing to increased treatment discontinuation among participants.
The findings suggest that CGRP-targeted therapies represent a superior first- or second-line option for chronic migraine prophylaxis due to their favorable balance of efficacy and patient adherence. Conversely, evidence for traditional agents like topiramate, valproate, and propranolol was often limited by a high risk of bias in the underlying trials, making their clinical utility less certain in a chronic population. The researchers emphasize that while these findings are promising, independent long-term studies are necessary to confirm safety and sustainability. Final treatment selection should prioritize individual patient profiles, cost-effectiveness, and clinician consultation.
Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-25-02221
References
Khalili, M., Haghdoost, F., Liaghatdar, A., Torabiardakani, K., Mahdian, F., Levit, T., Moradi, S., Hedayati, E., Ahmadi, F., Khademioore, S., Atkin-Jones, T., Sofi-Mahmudi, A., Patil, V., Mirzayeh Fashami, F., Mehmandoost, S., Kahlon, H. S., Couban, R. J., Prasad, K., Fereshtehnejad, S.-M., … Sadeghirad, B. (2026). Effectiveness and tolerability of pharmacologic prophylaxis for chronic migraine: A systematic review of randomized controlled trials. Annals of Internal Medicine, ANNALS-25-02221. https://doi.org/10.7326/ANNALS-25-02221
